Press release - Hirslanden Group successfully completes the placement fixed rate bond
PDF | 32.27 KB
Hirslanden Group successfully completes the placement of a CHF 145 million fixed rate bond at a coupon of 1.25% with UBS Investment Bank and Zürcher Kantonalbank acting as Joint Lead Managers.
The payment date of the newly issued bonds is 25 February 2021 with a 5-year term. The proceeds from the issue will be used to redeem the maturing CHF 145 million bond issued on 25 February 2015 with a coupon of 1.625%. The successful refinancing enables Hirslanden to lower its interest expense and to extend its debt maturity profile.
|Issuer||Hirslanden AG, Opfikon, Switzerland|
|Issue amount||CHF 145,000,000|
|Status||Senior unsecured debt|
|Term||5 years fixed|
|Payment date||25 February 2021|
|Listing||SIX Swiss Exchange|
The Hirslanden Group operates 17 hospitals in 10 cantons, many of which have an emergency department. It also operates 4 outpatient surgical units, 17 radiology institutes and 5 radiotherapy institutes. Together with public and private cooperation partners, Hirslanden focuses on the continuum of care and the promoting of high-quality, responsible, personalised and efficiently integrated healthcare. The Group has 2,506 affiliated doctors and 10,417 employees (including 498 permanently employed doctors). Hirslanden is the largest medical network in Switzerland. In the 2019/20 financial year, the Hirslanden Group achieved a turnover of CHF 1,804 million. During the 2019/20 financial year, the Group had treated 107,491 patients, amounting to a total of 471,717 inpatient days.
Hirslanden is synonymous with first-class medical care provided by highly qualified medical specialists with many years of experience. As a system provider, the Group stands out from the rest of the market: interdisciplinary medical centres of expertise and specialised institutes enable it to offer the best possible individualised treatment, particularly in highly complex cases. The Hirslanden Group was formed in 1990 through the merger of several hospitals. Since 2007, it is part of the international hospital group Mediclinic International plc, which is listed on the London Stock Exchange.
THIS PRESS RELEASE IS NOT FOR RELEASE IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES.
This document does not, and is not intended to, constitute or contain an offer or invitation to sell, and it is not soliciting offers to buy, bonds in any jurisdiction where such offer or sale is not permitted. In addition, the securities of Hirslanden AG have not been and will not be registered under the U.S. Securities Act and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of the United States Securities laws.
This document does not constitute a prospectus within the meaning of the Swiss Financial Services Act. Any decision to purchase any securities referred to herein should be solely based on the relevant prospectus to be published by Hirslanden AG and which will be available free of charge upon request at UBS AG, Investment Bank, Swiss Prospectus Switzerland, P.O. Box, 8098 Zurich, Switzerland, or can be ordered by telephone +41 44 239 47 03 (voicemail), fax +41 44 239 69 14 or by e-mail email@example.com.